US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Employee representatives on the Board of Directors

Unionen’s local branch, UA Svea, has appointed Sara Lenasdotter and Lisa Öberg as employee representatives to the Board of Directors of Apotea AB (publ) (“Apotea”). The employee representatives will be members of the Board from 1 September 2025.Sara Lenasdotter, born in 1992, is educated in packaging design at Brobygrafiska and has been working as a Designer at Apotea since 2021. Lisa Öberg, born in 1993, is educated as a graphic designer at Brobygrafiska and has been working as a Designer at Apotea since 2022. Apotea's Board of Directors consists of the members elected by the Annual

Apotea AB (publ) Interim report Q2 2025: Strengthened profitability and increased demand for prescription products

Net revenue for the second quarter increased by 9.9% (26.1) to SEK 1,826.2 million (1,661.1) and operating profit (EBIT) excluding items affecting comparability amounted to SEK 99.3 million (78.6), corresponding to an adjusted EBIT margin of 5.4% (4.7%).Second quarter (April 1 – June 30, 2025) · Net revenue increased by 9.9% (26.1) to SEK 1,826.2 million (1,661.1) · Gross margin was 28.0% (27.7) · Operating profit (EBIT) amounted to SEK 93.1 million (75.3), corresponding to an EBIT margin of 5.1% (4.5) · Operating profit (EBIT) excluding items affecting comparability amounted

Invitation to Apotea’s Q2 2025 webcast

Apotea AB (publ) (”Apotea”) will publish its Q2 2025 report at 07:30 am CEST on Friday the 18[th] of July. Investors, analysts, media and other interested parties are welcome to join a webcast and presentation of the interim report at 09:30 am the same day.The results for the period January – June 2025 will be presented by Pär Svärdson, CEO and Johan Mårild, CFO via a webcast held on 18[th] of July 2025 at 09:30 am. Link for webcast participation (no advance notification is necessary): https://apotea.events.inderes.com/q2-report-2025    If you wish to participate via teleconference,

Bulletin from Apotea AB’s (publ) Annual General Meeting on May 28, 2025

The Annual General Meeting (the “AGM”) of Apotea AB (publ), reg. no 556864-7324 (the “Company”) was held today, on 28 May 2025, whereupon the shareholders primarily resolved on the following matters with the required majority.Adoption of the income statement and balance sheet The AGM adopted the income statement and balance, as well as the consolidated income statement and consolidated balance sheet, for the financial year of 2024. Dispositions regarding the Company’s result The AGM resolved, in accordance with the board of directors’ proposal, that no dividend is to be paid for

Apotea AB (publ) Interim report Q1 2025: Improved profitability and solid growth in times of uncertainty

Net revenue for the first quarter increased by 15.2% to SEK 1,753.5 million (1,521.7) and operating profit (EBIT) amounted to SEK 92.4 million (62.2), corresponding to an EBIT margin of 5.3% (4.1%).First quarter (January 1 – March 31, 2025) · Net revenue increased by 15.2% to 1,753.5 SEKm (1,521.7) · Gross margin was 27.7% (27.3) · Operating profit (EBIT) amounted to 92.4 SEKm (62.2), corresponding to an EBIT margin of 5.3% (4.1) · There were no items affecting comparability in the period (-) · Operating profit (EBIT) excluding items affecting comparability amounted to 92.4

Apotea publishes annual and sustainability report for the financial year 2024

Apotea AB’s (publ) annual and sustainability report for the financial year 2024 is now available on the company's website: ir.apotea.seThe annual and sustainability report contains a summary of the past financial year and is available in both Swedish and English.For further information, please contact:Stefan Eriksson, deputy CEO & Investor RelationsE-mail: ir@apotea.seThis disclosure contains information that Apotea AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact

Notice to Annual General Meeting in Apotea AB (publ)

The Shareholders of Apotea AB (publ), reg. no 556864-7324 (the “Company”), are hereby summoned to the Annual General Meeting on Wednesday 28 May 2025 at 10.00 am at Nalen, Regeringsgatan 74, 111 38 Stockholm. Admission and registration will commence at 09.30 am.Right to attend and notification Shareholders who wish to attend the Annual General Meeting must: · be entered in the share register maintained by Euroclear Sweden AB no later than Tuesday 20 May 2025; and · notify the Company of their participation no later than Thursday 22 May 2025. Notice shall be made according to

The Nomination Committee's proposal for the Board of Directors of Apotea AB (publ)

Ahead of the annual general meeting of Apotea AB (publ) (“Apotea”) on May 28, 2025, the Nomination Committee hereby announces its proposal regarding the Chairman of the Board and other members of the Board.The Nomination Committee proposes that Cecilia Qvist, Anders Eriksson, Joanna Hummel, Jonas Hagströmer, Monica Lindstedt, Per Schlingmann and Pär Svärdson are re-elected as members of the Board of Directors of Apotea. Furthermore, the Nomination Committee proposes re-election of Cecilia Qvist as Chairman of the Board. Maria Curman and Henrik Forsberg Schoultz have informed the Nomination

Invitation to Apotea’s Q1 2025 webcast

Apotea AB (publ) (”Apotea”) will publish its Q1 2025 report at 07:30 am CEST on Thursday the 8th of May. Investors, analysts, media and other interested parties are welcome to join a webcast and presentation of the interim report at 09:30 am the same day.The results for the period January – March 2025 will be presented by Pär Svärdson, CEO, Sarah Ahnström, deputy CEO & COO, and Johan Mårild, CFO, via a webcast held on 8th of May 2025 at 09:30 am. Link for webcast participation (no advance notification is necessary): https://apotea.events.inderes.com/q1-report-2025 If you wish to

Apotea Sverige AB cooperates with the Swedish Competition Authority (Konkurrensverket) in an investigation on paid search advertising contacts

Following the decision by the Swedish Competition Authority (Konkurrensverket) today, on April 3, 2025, in case no. 288/2022 regarding the cooperation between a number of Swedish digital healthcare providers on the advertising of digital healthcare services, Apotea announces the following:The Swedish Competition Authority has launched an investigation on whether companies providing pharmacy services have been in contact regarding avoiding bidding on keywords corresponding to each other's brands in paid search advertising and whether such matters have been discussed in trade association

Apotea AB (publ) Year-end report 2024: Strong growth and increased profitability

Net revenue for the fourth quarter increased by 15.8% to SEK 1,732.9 million and operating profit (EBIT), excluding items affecting comparability for the period, amounted to SEK 66.9 million (34.3), corresponding to an adjusted EBIT margin of 3.9% (2.3%).Fourth quarter (October 1 – December 31, 2024) · Net revenue increased by 15.8% to 1,732.9 SEKm (1,495.9) · Gross margin was 27.0% (27.2%) · Operating profit (EBIT) amounted to 51.9 SEKm (34.3), corresponding to an EBIT margin of 3.0% (2.3%) · Operating profit (EBIT) excluding items affecting comparability amounted to 66.9

Invitation to Apotea’s presentation of the year-end report 2024

Apotea AB (publ) (”Apotea”) will Thursday the 6th of February publish its year-end report Q4 2024.  Investors, analysts, media and other interested parties are welcome to join a webcast and presentation of the interim report at 09:30 CET the same day.The results for the period January – December 2024 will be presented by Pär Svärdson, CEO, Sarah Ahnström, deputy CEO & COO, and Johan Mårild, CFO via a webcast held 6[th] of February 2025 at 09:30 CET. Link for webcast participation (no advance notification is necessary): https://apotea.events.inderes.com/q4-report-2024 The presentation

Number of shares and votes in Apotea

The number of shares and votes in Apotea AB (publ) (“Apotea”) has changed as a result of the issues in kind carried out in connection with the listing of Apotea’s ordinary shares on Nasdaq Stockholm on 6 December 2024.Through the issues in kind, the total number of shares has increased with 2,522,304 shares, from 102,742,950 shares to 105,265,254 shares, and the number of votes has increased with 1,447,444.8, from 102,742,950 to 104,190,394.8. The total number of shares is divided into 104,070,966 ordinary shares and 1,194,288 class C shares. The share capital has increased by SEK 12,611.52,

Decision from IMY after inspection of Apotea AB (publ)

Swedish Authority for Privacy Protection (Sw. Integritetsskyddsmyndigheten,“IMY”) has concluded its investigation into Apotea AB (publ)’s (“Apotea”) processing of personal data and compliance with GDPR. This following a self-notification of a personal data breach submitted by Apotea. In the investigation of two other pharmacy players, who also made a self-notification, IMY decided to issue administrative fines.Today, IMY announced a decision after the supervision of Apotea. IMY states that "in a combined assessment, IMY finds that it is a matter of a minor violation" of article 32.1 in the

Exercise of the overallotment option in Apotea and end of the stabilisation period in advance

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE.Carnegie Investment Bank AB (publ) (“Carnegie”) and Skandinaviska Enskilda Banken AB (publ) (“SEB”) have today notified Apotea AB (publ) (“Apotea” or the “Company”) and

Apotea announces the outcome of the offering and trading on Nasdaq Stockholm commences today

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE.Apotea AB (publ) (“Apotea” or the “Company”), Sweden’s largest online pharmacy[1], today announces the outcome of the offering of ordinary shares in the Company (the “

Apotea publishes prospectus and announces the price for the listing on Nasdaq Stockholm

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE.On 14 November 2024, Apotea AB (publ) (“Apotea” or the “Company”), Sweden’s largest online pharmacy, announced its intention to launch an initial public offering of the

Apotea intends to list its shares on Nasdaq Stockholm

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE.Apotea AB (publ) [1] (“Apotea” or the “Company”), Sweden’s largest online pharmacy, announces its intention to launch an initial public offering of the Company’s ordinary

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe